|Application ||WB, IF|
|Calculated MW||137910 Da|
|Other Names||Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein, MLN 19, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, CD340, ERBB2, HER2, MLN19, NEU, NGL|
|Target/Specificity||A phospho - specific peptide corresponding to residues surrounding tyrosine 877 of human HER2 was used as an immunogen. This antibody detects HER2 phosphorylated at tyrosine 877.|
|Format||50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||HER2 (ErbB2) Antibody Phospho (pY877) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||HER2, MLN19, NEU, NGL|
|Function||Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.|
|Cellular Location||Isoform 1: Cell membrane; Single-pass type I membrane protein. Cytoplasm, perinuclear region. Nucleus Note=Translocation to the nucleus requires endocytosis, probably endosomal sorting and is mediated by importin beta-1/KPNB1 Isoform 3: Cytoplasm. Nucleus.|
|Tissue Location||Expressed in a variety of tumor tissues including primary breast tumors and tumors from small bowel, esophagus, kidney and mouth.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
HER2 / ErbB2 is one of the four members of the ErbB receptor family of transmembrane receptor-like tyrosine kinases (1). The kinase activity of ErbB2 can be activated without ligand if it is overexpressed, and by association with other ErbB proteins (2). Overexpression of ErbB2 is detected in almost 40% of human breast cancers (3). ErbB2 is one of the major targets for the treatment of breast cancer and other carcinomas. Autophosphorylation did not modulate receptor turnover. A Tyr----Phe substitution of ErbB-2 Tyr-877 homologous to pp60c-src Tyr-416 did not alter ErbB-2 biological and biochemical properties, thus excluding the possibility that phosphorylation of this residue, located in the kinase domain, modulates ErbB-2 gp185 catalytic function (4).
1. Muthuswamy, S. K., et al. Mol. Cell. Biol. 19: 6845-6857 (1999).
2. Qian, X., et al. Proc. Natl. Acad. Sci. USA 91: 1500
3. Dittadi, R, et al. J. Natl. Cancer Inst. 92: 1443-1444 (2000).
4. Klapper, L. N., et al. Cancer Res. 60: 3384-3388 (2000).
5. Segatto O, et al. New Biol 2(2):187-95, 1990
If you have any additional inquiries please email technical services at firstname.lastname@example.org.